News Release

Chugai Announces 2026 2nd Quarter Results

TOKYO, July 24, 2026 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced its financial results for the second quarter of fiscal year 2026.

- Core revenue of ¥663.3 billion (+14.7%), core operating profit of ¥329.1 billion (+21.0%), and core net income of ¥238.4 billion (+23.2%) were achieved (all changes year-on-year)
- Strong growth in domestic and overseas sales, combined with a significant increase in other revenue driven by one-time income, and royalty income related to Hemlibra® and NEMLUVIO®, resulted in increased revenue and profit year-on-year
- Achieved eight regulatory filings in Japan during the first half of the year, progressing steadily toward achieving the highest number of filings ever planned
- R&D activities progressed steadily across both early- and late-stage development, including Chugai-originated projects
  - For NXT007, which is expected to become a next-generation growth driver, two Phase III studies were initiated
  - For AQUA07, the third macrocyclic peptide project, entry into the clinical stage was achieved, with dosing in a Phase I study in *ALK*-positive non-small cell lung cancer expected to start shortly
  - For Enspryng®, developed using Chugai's proprietary antibody engineering technologies, the U.S. FDA accepted the regulatory application for thyroid eye disease (TED) and granted Priority Review designation
- Regarding products out-licensed to third parties, global market penetration of Chugai-originated new products advanced
  - Export sales and royalty income from NEMLUVIO (nemolizumab), a humanized anti-human IL-31 receptor A monoclonal antibody out-licensed to Galderma, drove revenue growth
  - As for Foundayo™ (orforglipron), an oral GLP-1 receptor agonist out-licensed to Eli Lilly, prescriptions were driven in the U.S. primarily by GLP-1 naïve patients, and the oral anti-obesity drug market is expanding. Chugai commenced recognition of royalty income from the product in the second quarter

Refer to the information below for details on the financial results:

Quarterly Reports / Finance Reports
https://www.chugai-pharm.co.jp/english/ir/reports_downloads/tanshin.html

CHUGAI PHARMACEUTICAL CO., LTD. Corporate Communications Dept.
1-1 Nihonbashi-Muromachi 2-chome, Chuo-ku, Tokyo 103-8324 Japan
Media Relations Group TEL: +81-(0)3-3273-0881 E-mail: pr@chugai-pharm.co.jp
Investor Relations Group TEL: +81-(0)3-3273-0554 E-mail: ir@chugai-pharm.co.jp

Presentation Materials

In addition to Chugai's business and financial performance, these materials provide updates on our research and development pipeline. Videos and transcripts (including Q&A) will be made available at a later date.

https://www.chugai-pharm.co.jp/english/media/conference.html

[2026 Second Quarter Results]

Core results (Billion JPY)	2026 Jan-Jun	2025 Jan-Jun	% change
Revenue	**663.3**	**578.5**	**+14.7%**
Domestic sales	237.9	223.3	+6.5%
Overseas sales	328.6	288.1	+14.1%
Other revenue	96.8	67.0	+44.5%
Operating profit	**329.1**	**272.0**	**+21.0%**
Net income	**238.4**	**193.5**	**+23.2%**

###